MARKET WIRETradingView • 19h ago
PharmaCyte Biotech, Inc. Estimates – NASDAQ:PMCBTradingView report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
Why PMCB Stock surged +2.71% Today — RQD Quant Desk Flash
$0.31 +2.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.31
PharmaCyte Biotech Inc. (PMCB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $3.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PMCB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, PharmaCyte Biotech Inc. (NASDAQ: PMCB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.31 (+2.71% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMCB ranks #664 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PMCB compare to LIMN and CRIS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PMCB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.2%. By comparison, LIMN (Liminatus Pharma Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, PMCB leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PMCB?
▼
Per PMCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001157075), PharmaCyte Biotech Inc. generated $19.2M in revenue (+56.6% YoY), -$19.4M in net income, and -$5.2M in free cash flow against $55.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.31 (+0.30%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMCB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY PMCB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 32.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.36-5.6% Next Q
42
Q2 (-2Q)Grade E$0.34+0% Next Q
39
Q3 (-1Q)Grade E$0.34-8.8% Next Q
37
CurrentGrade E$0.31-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PMCB Turnaround Squeeze
While PMCB currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.41) and Max Pain ($0.33) forces dealer call-delta covering toward $1.59.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMCB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PMCB Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PMCB Stock surged +2.71% Today — RQD Quant Desk Flash
PharmaCyte Biotech Inc. (PMCB) surged +2.71% to $0.31, trading at 2% of its 52-week range ($0.3 – $1.51). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.3 – $1.51) with RSI-14 at 32.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PMCB Headlines & Catalysts
CATALYSThttps://www.siam.in/ • 22h ago
PharmaCyte Biotech (PMCB) Ticks Up 5.45% to $0.36 as Micro-Cap Presses Against Resistance - AD Line Divergencehttps://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Top U.S. Stock Losers: Biggest Price DeclinesTradingKey report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
ICICI Bank (IBN) Trades Nearly Flat at $27.89, Boxed Between $26.50 Support and $29.28 Resistance - Strangle Setuphttps://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
PharmaCyte Biotech, Inc. (PMCB) Stock Price Prediction for 2026, 2030-2040Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
PharmaCyte Biotech, Inc. Stock Price Today | PMCB Live Chart & NewsTraders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Live PharmaCyte Biotech, Inc. (PMCB) Technical AnalysisTraders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMCB)
- ✓Walkthrough of PMCB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PMCB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.21%▼ DESCENDING CHANNEL
2026-11-03O $0.33H $0.33L $0.30C $0.31VOL 121.7K
RES: $0.38SUP: $0.16SMA50: $0.41SMA200: $0.64
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PMCB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PMCB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PMCB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PMCB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMCB)
Health Care Rank #664 of 1016
⚔️ LIMN vs PMCB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PMCB vs. LIMN, CRIS, CLDI, BTTC)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, PharmaCyte Biotech Inc. (PMCB) ranks #664 by composite RQD confidence (34/100, grade E) and #972 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, PMCB leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with PMCB at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PMCB
ACTIVE
PharmaCyte Biotech Inc. | E | 34/100 | — | — | -30.2% | +2.71% | $3.2M | Benchmark Subject |
| LIMN Liminatus Pharma Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -10.64% | $3.8M | /limn-vs-pmcb → |
| CRIS Curis Inc. | E | 27/100 | — | — | -35.0% | +10.17% | $4.0M | /cris-vs-pmcb → |
| CLDI Calidi Biotherapeutics Inc. | E | 31/100 | — | — | -35.0% | -4.36% | $2.5M | /cldi-vs-pmcb → |
| BTTC Black Titan Corporation | D- | 38/100 | — | — | — | -3.17% | $4.8M | /bttc-vs-pmcb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001157075In its most recent audited fiscal period (FY2025, filed 2026-04-30), PharmaCyte Biotech Inc. (PMCB) reported GAAP revenue of $19.2M (+56.6% vs. FY2024 revenue of $12.3M , and -19.6% cumulative change since FY2023) , GAAP net income of -$19.4M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (-73.0% YoY). On the balance sheet, PMCB closed FY2025 with $55.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $19.2M | -$19.4M | -$5.2M | -$5.2M | $55.9M | — |
| FY2024 (FY) | 2025-04-30 | $12.3M | $30.7M | -$3.0M | -$3.0M | $43.8M | — |
| FY2023 (FY) | 2024-04-30 | $23.9M | $333.8K | -$2.2M | -$2.2M | — | — |
3. PMCB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, PharmaCyte Biotech Inc. (NASDAQ: PMCB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.31 (+2.71% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMCB ranks #664 in composite RQD confidence.
How does PMCB compare to LIMN and CRIS in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PMCB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.2%. By comparison, LIMN (Liminatus Pharma Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, PMCB leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PMCB?
Per PMCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001157075), PharmaCyte Biotech Inc. generated $19.2M in revenue (+56.6% YoY), -$19.4M in net income, and -$5.2M in free cash flow against $55.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PMCB trading relative to its 50-day, 200-day, and 52-week technical levels?
PMCB last traded at $0.31 (+2.71% on volume of 40,845 shares), positioning the stock -24.39% below its 50-day simple moving average ($0.41) and -51.56% below its 200-day simple moving average ($0.64). Across its 52-week range of $0.30 to $1.51, PMCB sits at the 0.8% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PMCB — PharmaCyte Biotech Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:57Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
PMCB scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows. The Fundamental Cash Engine scores 5 of 20, reflecting ROIC of -30. Whale/13F Flow scores 10 of 20, indicating some institutional accumulation and options positioning, though the source does not provide holder detail to confirm the size or direction of that activity. Insider Conviction scores 5 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow that the rating characterizes as weak support. Macro Regime Fit scores 8 of 20 with a Beta of 1.0 and sector sensitivity noted, meaning the stock moves in line with the market but without a defensive profile. Forensic Balance Sheet scores 7 of 20, with an Altman Z-Score of 0.2, a Piotroski F-Score of 2 out of 9, and Debt/Equity of 0.5, all of which point to elevated financial distress risk. Taken together, the prospective investor faces a sub-dollar, micro-cap equity with negative returns on capital, zero free cash flow yield, and weak forensic signals.
2. Business Model, Unit Margins & SEC Financial Trajectory
PharmaCyte Biotech Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances), per the SEC profile. Reported revenue is — in each listed period, . — for how the company makes money.
Revenue is zero across all three periods and operating income is negative in each. Net income swings from $0.3M in FY 2023 to $30.7M in FY 2024 and then to -$19.4M in FY 2025, a pattern the source does not explain. Per the market data, gross, operating, and net margins are all 0%, and ROIC is -30.2%. The Roarable RQD rating reports an Altman Z-Score of 0.2 and a Piotroski F-Score of 2 out of 9, signaling distress and weak fundamentals. The balance sheet shows Debt/Equity of 0.5, while reported debt is N/A in the SEC financials.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Shares trade near $0.33 with institutional accumulation and options positioning scored at 10 of 20 in the RQD rating. With Fundamental Cash Engine at 5/20 (ROIC -30.2%, FCF yield —) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $0.30 – $1.51 52-week range.
- 🐻 Primary Bear Case: Zero revenue, -30.2% ROIC, and an Altman Z-Score of 0.2 signal a business consuming capital with high distress risk. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), PMCB carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: What drove the swing in net income from $0.3M in FY 2023 to $30.7M in FY 2024 and then to -$19.4M in FY 2025?
- Key Question #2: What is the reported debt balance, since the SEC financials list debt as N/A while Debt/Equity is 0.5?
- Key Question #3: What is the company's cash runway relative to its -$5.2M FY 2025 free cash flow burn?
PMCB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for PharmaCyte Biotech Inc. (PMCB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 19h ago
PharmaCyte Biotech, Inc. Estimates – NASDAQ:PMCB TradingView report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 22h ago
PharmaCyte Biotech (PMCB) Ticks Up 5.45% to $0.36 as Micro-Cap Presses Against Resistance - AD Line Divergence https://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Top U.S. Stock Losers: Biggest Price Declines TradingKey report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
ICICI Bank (IBN) Trades Nearly Flat at $27.89, Boxed Between $26.50 Support and $29.28 Resistance - Strangle Setup https://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
PharmaCyte Biotech, Inc. (PMCB) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
PharmaCyte Biotech, Inc. Stock Price Today | PMCB Live Chart & News Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Live PharmaCyte Biotech, Inc. (PMCB) Technical Analysis Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PMCB Bull vs. Bear Conversation Board — What's Your Call at $0.31?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMCB 🐻 33% BEARISH CONVICTION
MI MidwestValue Fundamental Long-Only 🐂 BULLISH
🎯 Target: $0.39 (+30.0%)
📌 Pinned Debate Shares trade near $0.33 with institutional accumulation and options positioning scored at 10 of 20 in the RQD rating.
The street is overcomplicating PharmaCyte Biotech Inc. (PMCB). Shares trade near $0.33 with institutional accumulation and options positioning scored at 10 of 20 in the RQD rating.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 7/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.32.
RetailWhale_TX 🐂 BULL
@FadeTheHype Shorting a 9/20 institutional whale-flow stock at $0.30 is dangerous when funds are rotating into Health Care.
FA FadeTheHype Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $0.25 (-16.7%)
Spot @ $0.30 Zero revenue, -30.2% ROIC, and an Altman Z-Score of 0.2 signal a business consuming capital with high distress risk.
I respect the product at PharmaCyte Biotech Inc., but the stock at $0.30 is a different story. Zero revenue, -30.2% ROIC, and an Altman Z-Score of 0.2 signal a business consuming capital with high distress risk.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?